

Adult Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (DR-TB '22)	WHO Rapid Communication (DR-TB '24)	EML submitted	EML (2025)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Amikacin 500mg/2mL vial	Yes	Yes	Yes	Yes	N/A	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Amoxicillin/clavulanate 500mg/125mg tablet	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Bedaquiline 100mg tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Clofazimine 50mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	
Clofazimine 100mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	
Cycloserine 250mg capsule	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Delamanid 50mg tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	

DR-TB: Drug-Resistant TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025

Adult Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (DR-TB '22)	WHO Rapid Communication (DR-TB '24)	EML submitted	EML (2025)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Ethambutol 400mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Ethionamide 250mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Imipenem/cilastatin 500/500mg vial	Yes	Yes	Yes	Yes	N/A	N/A	N/A	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Isoniazid 300mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Levofloxacin 250mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Levofloxacin 500mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Levofloxacin 750mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	

DR-TB: Drug-Resistant TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025

Adult Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (DR-TB '22)	WHO Rapid Communication (DR-TB '24)	EML submitted	EML (2025)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Linezolid 600mg tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Meropenem 1000mg vial	Yes	Yes	Yes	Yes	N/A	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Moxifloxacin 400mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
PAS Sodium 4gm/5.52gm powder	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Pretomanid 200mg tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Protionamide 250mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Pyrazinamide 400mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	

DR-TB: Drug-Resistant TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025

Adult Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (DR-TB '22)	WHO Rapid Communication (DR-TB '24)	EML submitted	EML (2025)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Pyrazinamide 500mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Streptomycin 1000mg vial	Yes	Yes	Yes	Yes	N/A	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Terizidone 250mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	

DR-TB: Drug-Resistant TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025

Adult Drug-Susceptible TB Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (DS-TB '22)	EML submitted	EML (2025)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Ethambutol 400mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Ethambutol/Isoniazid/Pyrazinamide/ Rifampicin 275/75/400/150mg tablet/ capsule	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	
Ethambutol/Isoniazid/Rifampicin 275/75/150mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	
Isoniazid 100mg tablet	Yes	Yes	Yes	Yes	N/A	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Isoniazid 300mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Isoniazid/Rifampicin 75/150mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	
Moxifloxacin 100mg dispersible tablet	N/A	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	

DS-TB: Drug-Susceptible TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025

Adult Drug-Susceptible TB Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (DS-TB '22)	EML submitted	EML (2025)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Moxifloxacin 400mg tablet/capsule	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	Yes
Pyrazinamide 400mg tablet/capsule	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	Yes
Pyrazinamide 500mg tablet/capsule	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	Yes
Rifabutin 150mg capsule	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	No
Rifampicin 150mg capsule	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	No
Rifampicin 300mg capsule	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	No
Rifapentine 150mg tablet	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	Ineligible for inclusion

DS-TB: Drug-Susceptible TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025

Adult Drug-Susceptible TB Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (DS-TB '22)	EML submitted	EML (2025)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Rifapentine 300mg	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	Yes
Rifapentine/Isoniazid 300mg/300mg tablet	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	Yes
Rifapentine/Isoniazid/Moxifloxacin 300/75/100mg tablet	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	Ineligible for inclusion
Rifapentine/Isoniazid/Moxifloxacin/ Pyrazinamide 300/75/100/375mg tablet	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	Ineligible for inclusion

DS-TB: Drug-Susceptible TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025

Adult TB Preventive Treatment Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (TPT '20)	WHO Guidelines (TPT '24)	EML submitted	EML (2025)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Isoniazid 300mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Isoniazid/Rifampicin 75/150mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	
Rifampicin 150mg capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	
Rifampicin 300mg capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	
Rifapentine 150mg tablet	Yes	Yes	Yes	Yes	N/A	Ineligible for inclusion	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Rifapentine 300mg	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Rifapentine/Isoniazid 300mg/300mg tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	

LTBI: Latent TB Infection
TPT: TB Preventive Treatment
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025

Adult TB Preventive Treatment Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (TPT '20)	WHO Guidelines (TPT '24)	EML submitted	EML (2025)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Sulfamethoxazole/Trimethoprim/ Isoniazid/Pyridoxine 800/160/300/ 25mg tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	

LTBI: Latent TB Infection
TPT: TB Preventive Treatment
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025

Pediatric Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (Children & Adolescent '22)	WHO Rapid Communication (DR-TB '24)	EMLc submitted	EMLc (2025)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Amoxicillin/clavulanate 500mg/125mg tablet	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Amoxicillin/clavulanic acid 250mg/62.5mg/5mL oral suspension	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion	Ineligible for inclusion	No	No
Bedaquiline 20mg tablet	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	Yes	Yes
Bedaquiline 100mg tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Clofazimine 50mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	Yes
Cycloserine 125mg capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	Yes
Delamanid 25mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	Yes	Yes

DR-TB: Drug-Resistant TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025

Pediatric Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (Children & Adolescent '22)	WHO Rapid Communication (DR-TB '24)	EMLc submitted	EMLc (2025)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Delamanid 50mg tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	Yes
Ethambutol 50mg dispersible tablet	Yes	Yes	No	No	N/A	N/A	Yes	Yes	N/A	Ineligible for inclusion	No	No
Ethambutol 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Ethambutol 100mg tablet	Yes	Yes	Yes	Yes	N/A	Ineligible for inclusion	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Ethionamide 125mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Isoniazid 50mg dispersible tablet	Yes	Yes	No	No	N/A	Ineligible for inclusion	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	No	No
Isoniazid 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes

DR-TB: Drug-Resistant TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025

Pediatric Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (Children & Adolescent '22)	WHO Rapid Communication (DR-TB '24)	EMLc submitted	EMLc (2025)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Isoniazid 100mg tablet	Yes	Yes	Yes	Yes	N/A	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Isoniazid 300mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Levofloxacin 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Linezolid 150mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Linezolid 600mg tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Meropenem 1000mg vial	Yes	Yes	Yes	Yes	N/A	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Moxifloxacin 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes

DR-TB: Drug-Resistant TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025

Pediatric Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (Children & Adolescent '22)	WHO Rapid Communication (DR-TB '24)	EMLc submitted	EMLc (2025)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Moxifloxacin 400mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
PAS Sodium 4gm/5.52gm powder	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Pyrazinamide 150mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes

DR-TB: Drug-Resistant TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025

Pediatric Drug-Susceptible TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2025)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Ethambutol 50mg dispersible tablet	Yes	Yes	No	No	N/A	N/A	Yes	Yes	N/A	Ineligible for inclusion	No	
Ethambutol 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Ethambutol 100mg tablet	Yes	Yes	Yes	Yes	N/A	Ineligible for inclusion	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Ethionamide 125mg dispersible tablet	N/A	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Isoniazid 50mg dispersible tablet	Yes	Yes	No	No	N/A	Ineligible for inclusion	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	No	
Isoniazid 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Isoniazid 100mg tablet	Yes	Yes	Yes	Yes	N/A	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	

DS-TB: Drug-Susceptible TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025

Pediatric Drug-Susceptible TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2025)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Isoniazid 300mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Pyrazinamide 150mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Rifampicin 20mg/mL oral liquid	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	Yes	No	Ineligible for inclusion	No	
Rifampicin/Isoniazid 75/50 dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	
Rifampicin/Isoniazid/ Pyrazinamide 75/50/150mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	

DS-TB: Drug-Susceptible TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025

Pediatric TB Preventive Treatment Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (TPT '24)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2025)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Isoniazid 50mg dispersible tablet	Yes	Yes	No	No	N/A	Ineligible for inclusion	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	No	
Isoniazid 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Isoniazid 100mg tablet	Yes	Yes	Yes	Yes	N/A	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Isoniazid 300mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Levofloxacin 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Rifampicin 20mg/mL oral liquid	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	Yes	No	Ineligible for inclusion	No	
Rifampicin/Isoniazid 75/50 dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	
Rifapentine 150mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	

LTBI: Latent TB Infection
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025

Pediatric TB Preventive Treatment Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (TPT '24)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2025)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Rifapentine 150mg tablet	Yes	Yes	Yes	Yes	N/A	Ineligible for inclusion	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Rifapentine 300mg	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Rifapentine/Isoniazid 300mg/300mg tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Sulfamethoxazole/Trimethoprim/Isoniazid/Pyridoxine 400/80/150/12.5mg tablet	Yes	Yes	N/A	No	Yes	No	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	

LTBI: Latent TB Infection
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025

Formulations no longer recommended TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

	EML	EMLC	WHO PQ EOI	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP recommended	GDF Catalog
Medicines							
Amikacin 100mg vial	Removed	Removed	No	Ineligible for inclusion	No	Ineligible for inclusion	Ineligible for inclusion
Amikacin 1000mg vial	Removed	Removed	No	Ineligible for inclusion	No	Ineligible for inclusion	Ineligible for inclusion
Amoxicillin/clavulanate 875mg/125mg tablet	No	No	No	Ineligible for inclusion	Yes	Ineligible for inclusion	Removed
Amoxicillin/clavulanic acid 125mg/31.25mg/5mL oral suspension	Removed	Removed	No	Ineligible for inclusion	Yes	Ineligible for inclusion	No
Bedaquiline 100mg dispersable tablet	No	No	Removed	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Capreomycin 500mg vial	No	No	Removed	Removed	Removed	Ineligible for inclusion	Removed
Capreomycin 750mg vial	No	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Capreomycin 1000mg vial	Removed	Removed	Removed	No	Removed	Ineligible for inclusion	Removed

Status

- Yes
- No
- Ineligible for inclusion
- Removed
- Rejected
- N/A

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: September 2025

Formulations no longer recommended TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

	EML	EMLC	WHO PQ EOI	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP recommended	GDF Catalog
Medicines							
Delamanid 50mg dispersible tablet	N/A	No	Removed	No	No	Ineligible for inclusion	Ineligible for inclusion
Ethambutol 25mg/mL oral liquid	Removed	Removed	No	Ineligible for inclusion	No	Ineligible for inclusion	Ineligible for inclusion
Ethambutol 200mg tablet/capsule	No	No	Removed	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Ethambutol 275mg tablet/capsule	No	No	Removed	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Ethambutol 1000mg vial	Rejected	Rejected	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Ethambutol 2000mg vial	Rejected	Rejected	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Ethambutol/Isoniazid 400/150mg tablet/capsule	Removed	Removed	Removed	Yes	Removed	Ineligible for inclusion	Removed
Ethionamide 125mg tablet/capsule	Removed	Removed	No	Yes	Yes	Ineligible for inclusion	No

EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025

Formulations no longer recommended TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

	EML	EMLC	WHO PQ EOI	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP recommended	GDF Catalog	Status
Medicines								
Gatifloxacin 200mg tablet								
Gatifloxacin 400mg tablet								
Imipenem/cilastatin 250/250mg vial								
Imipenem/cilastatin/clavulanate 500/500/125 mg vial								
Isoniazid 50mg tablet scored								
Isoniazid 50mg/5mL oral liquid								
Isoniazid 100mg/5mL oral liquid								
Isoniazid 100mg/mL vial								

EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025

Formulations no longer recommended TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

	EML	EMLC	WHO PQ EOI	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP recommended	GDF Catalog
Medicines							
Isoniazid/Pyrazinamide/Rifampicin 75/400/150mg tablet/capsule	Removed	N/A	No	Ineligible for inclusion	No	Ineligible for inclusion	Ineligible for inclusion
Isoniazid/Pyrazinamide/Rifampicin 150/500/150mg tablet/capsule	Removed	No	Removed	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Isoniazid/Rifampicin 150/150mg tablet/capsule	Removed	No	Removed	Yes	Removed	Ineligible for inclusion	Removed
Isoniazid/Rifampicin 150/300mg tablet/capsule	Yes	N/A	Removed	Yes	Yes	Ineligible for inclusion	No
Kanamycin 500mg vial	No	No	Removed	Yes	Removed	Ineligible for inclusion	Removed
Kanamycin 1000mg vial	Removed	Removed	Removed	Yes	Removed	Ineligible for inclusion	Removed
Linezolid 20mg/mL oral suspension	Removed	Removed	Removed	No	No	Ineligible for inclusion	No
Linezolid 400mg tablet	Removed	Removed	No	Ineligible for inclusion	No	Ineligible for inclusion	Ineligible for inclusion

Status

- Yes
- No
- Ineligible for inclusion
- Removed
- Rejected
- N/A

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: September 2025

Formulations no longer recommended TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

	EML	EMLC	WHO PQ EOI	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP recommended	GDF Catalog
Medicines							
Linezolid injection 2mg/mL in 300mL bag	Removed	Removed	No	Ineligible for inclusion	Yes	Ineligible for inclusion	No
Meropenem 500mg vial	Yes	Yes	No	Ineligible for inclusion	No	Ineligible for inclusion	Ineligible for inclusion
Meropenem/clavulanate 1000 mg/125 mg vial	No	No	Removed	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
PAS 4gm granules	Removed	Removed	Removed	No	Yes	Ineligible for inclusion	Ineligible for inclusion
PAS 500mg tablet	Removed	Removed	No	Ineligible for inclusion	No	Ineligible for inclusion	Ineligible for inclusion
PAS Injection	Rejected	Rejected	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
PAS Sodium 4gm/9.2gm powder	No	No	No	No	Yes	Ineligible for inclusion	No
PAS Sodium 100gm powder	No	No	No	No	Yes	Ineligible for inclusion	No

EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025

Formulations no longer recommended TB Medicines Dashboard

This Dashboard has been developed by [Stop TB Partnership/Global Drug Facility](#) in collaboration with other Tuberculosis Stakeholders.
[Stop TB Partnership/Global Drug Facility](#) licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

	EML	EMLC	WHO PQ EOI	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP recommended	GDF Catalog	Status
Medicines								
Pyrazinamide 30mg/mL oral liquid	Removed	Removed	No	Ineligible for inclusion	No	Ineligible for inclusion	Ineligible for inclusion	
Pyrazinamide 150mg tablet scored	Removed	Removed	No	Ineligible for inclusion	No	Ineligible for inclusion	Ineligible for inclusion	
Pyrazinamide 250mg tablet/capsule	No	No	Removed	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	
Rifampicin 450mg tablet	No	No	No	Ineligible for inclusion	Yes	Ineligible for inclusion	No	
Rifampicin 600mg vial	Rejected	Rejected	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	
Rifapentine 300mg scored, dispersible	No	No	Removed	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	
Rifapentine/Isoniazid 150mg/150mg dispersible tablet	No	No	Removed	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	
Rifapentine/Isoniazid 300mg/300mg dispersible tablet	No	No	Removed	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	

EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025

Formulations no longer recommended TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

	EML	EMLc	WHO PQ EOI	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP recommended	GDF Catalog
Medicines							
Streptomycin 750mg vial	No	No	Removed	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Terizidone 300mg tablet/capsule	No	No	Removed	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Terizidone 500mg tablet	No	N/A	Removed	No	No	Ineligible for inclusion	Ineligible for inclusion

EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel
SRA: Stringent Regulatory Authority
WHO PQ: World Health Organization Prequalification of Medicines Programme
Version: September 2025